News & Views |
Featured
-
-
Article
| Open AccessA TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2
A nanoparticle-based adjuvant incorporating a Toll-like receptor 7 agonist elicits cross-reactive antibodies for both dominant and subdominant epitopes and enhances immune responses against multiple variants of influenza and SARS-CoV-2.
- Qian Yin
- , Wei Luo
- & Mark M. Davis
-
News & Views |
Next-generation malarial vaccines
A vaccine platform developed from a synthetic polymeric glyco-adjuvant and reversibly conjugated to an antigen was shown to target dendritic cells leading to cellular and humoral immune response against malaria.
- Yvette van Kooyk
-
Article |
Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity
A vaccine platform has been developed from a polymeric glyco-adjuvant conjugated to an antigen, and is now shown to target dendritic cells via mannose-binding receptors and generate potent cellular and humoral immune response against malaria.
- D. Scott Wilson
- , Sachiko Hirosue
- & Jeffrey A. Hubbell
-
News & Views |
Softness makes it better
An effective adjuvant for the induction of humoural and cellular immunity is achieved by a Pickering emulsion formulation that allows pliability and mobility of loaded antigens.
- Herman F. Staats
- & David J. Burkhart